首页> 外文期刊>Journal of Medicinal Chemistry >Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles
【24h】

Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles

机译:一系列4-[((2,4-二氯-5-甲氧基苯基)氨基] -7-呋喃基-3-喹啉甲腈的合成及Src激酶抑制活性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Compound 1 (SKI-606, bosutinib), a 7-alkoxy-4-[(2,4-dichloro-5-methoxyphenyl)amino]-3-quinolinecarbonitrile, is a potent inhibitor of Src kinase activity. We previously reported that analogs of 1 with thiophene groups at C-7 retained the Src activity of the parent compound. The corresponding C-7 furan analogs were prepared and it was found that the 3,5-substituted furan analog had increased activity compared to that of the 2,5-substituted furan isomer. Addition of a methoxy group at C-6 decreased the Src inhibitory activity of the C-7 2,5-substituted furan analog but increased the activity of the C-7 3,5-substituted furan isomer. This compound, 10, was a more potent Src inhibitor than 1 in both enzymatic and cell-based assays. The kinase selectivity profile of 10 was similar to that of 1, with 10 also inhibiting the activity of Abl and Lck. When tested in a solid tumor xenograft model, 10 had comparable oral activity to that of 1.
机译:化合物1(SKI-606,波舒替尼)是一种7-烷氧基-4-[(2,4-二氯-5-甲氧基苯基)氨基] -3-喹啉甲腈,是Src激酶活性的有效抑制剂。我们先前曾报道,在C-7处具有噻吩基的1的类似物保留母体化合物的Src活性。制备相应的C-7呋喃类似物,发现与2,5-取代的呋喃异构体相比,3,5-取代的呋喃类似物具有增加的活性。在C-6处加甲氧基降低了C-7 2,5-取代的呋喃类似物的Src抑制活性,但增加了C-7 3,5-取代的呋喃异构体的活性。在酶促和基于细胞的测定中,该化合物10是比1更有效的Src抑制剂。 10的激酶选择性谱与1相似,其中10也抑制Abl和Lck的活性。在实体瘤异种移植模型中测试时,有10种口服活性与1种口服活性相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号